

SUBJECT INDEX

- Abstinence, 995
 Acetaminophen, 513
 Acetylcholine, 763
 Acetylcholinesterase, 929
 Acids, 523
 Acrosome reaction, 609
 Actin, 617
 Active avoidance, 61
 Activity pattern analyses, 959
 Addiction, 887
 Adenosine, 33
 Adenosine A1 receptors, 33
 Adenosine receptor, 811
 Adenylate cyclase, 565
 Adrenal medulla, 593
 Adrenalectomy, 861
 α -Adrenoceptor antagonist, 709
 Affect, 229, 443
 Aggression, 835
 Aging, 949
 Agoraphobia, 959
 AIDS, 695
 Akinesia, 261
 Alcohol, 867
 Alcohol drinking, 923
 Alcohol preference, 923
 Alcohol sensitivity, 409
 Aldosterone, 861
 Aliesterase, 929
 Alpha-1 adrenoceptors, 125
 Alveolar macrophages, 643
 Ames test, 541
 Amide compound, 465
 Amino acid diet, 83
 Aminoalkylindole analogs, 471
 Aminooxyacetic acid, 287
 AMPA, 21
 Amphetamine, 21, 181, 881, 915, 983
 d-Amphetamine, 215, 317, 775
 Analgesia, 197, 297, 317, 479
 Analysis, 465
 Anesthesia, 767
 Anhedonia, 1001
 Animal model of CNS plasticity, 367
 Anorectic, 75
 Anorexia, 53, 83, 875
 ANP, 61
 Antagonist, 893
 Anterior pituitary, 603
 Anticholinesterase, 17
 Anticonflict, 787, 795
 Anticonvulsant effect, 581
 Antidepressant, 69
 Antiemetic, 695, 1033
 Antimuscarinic, 345
 Antinociception, 479, 509, 581
 Antipsychotic, 89
 Anxiety, 7, 819
 Anxiolytic, 89, 733, 739
 Aphrodisiac, 221
 Apomorphine, 317
 Approach response, 323
 Arachidonic acid, 559
 Arecoline, 763
 Arousal, 215, 229
 Atrial natriuretic peptide, 237
 Atrium, 345
 Atropine, 745
 Attack, 781
 Autoradiography, 339
 Autoreceptors, 901
 Autotomy, 301
 Avoidance behavior, 237
 Balanced-placebo design, 115
 Barbiturate synergism, 541
 Bed nucleus of the stria terminalis, 977
 Behavior, 279
 Behavioral stimulation, 291
 Behavioral thermoregulation, 709
 Benzodiazepine, 109, 429, 581
 Beta-endorphin, 229, 449
 Beta-oxidation, 523
 Bicuculline, 109, 287
 Bicyclic analogs, 471
 Bioassay, 629
 Bioavailability of THC, 497
 Biodistribution, 503
 Blood pressure, 701
 Blood-brain barrier, 771
 Body temperature, 129, 157, 249, 581, 709
 Brain, 767
 Brain calcium, 423
 Brain reward, 571
 Brain stimulation reward, 273
 Brain temperature, 33
 (-)-5'-Bromo- Δ^8 -THC, 509
 Buspirone, 733, 787
 Butt length, 657
 Caffeine, 21, 121, 811, 847
 Caffeine pharmacokinetics, 723
 Calcium-calmodulin-dependent-catecholamine synthesis, 423
 Calcium channels, 949
 Cancer chemotherapy, 695
 Cannabichromene, 533
 Cannabidiol, 517, 523, 533, 541, 581, 609, 701
 Cannabielsoin, 541
 Cannabigerol, 533
 Cannabinoid, 461, 479, 491, 517, 547, 553, 571, 593, 609, 617, 637, 695
 Cannabinoid pharmacological profile, 471
 Cannabinoid receptor, 565
 Cannabinol, 533, 609
 Cannabis, 97, 487, 517, 571, 671, 683, 689, 701
 Cannabis in the Bible, 461
 Capillary column GC, 517
 Capsaicin, 163
 Capsules of CBD and sesame oil, 517
 Carbohydrate, 861
 β -Carbolines, 329
 Carbon monoxide, 651, 657
 Cardiovascular responses, 157
 Cat, 345, 367, 533
 Catalepsy, 559, 829, 1001
 Cataleptogenic effects, 465
 Catalytic hydrogenation, 461
 Catecholamine, 593, 937
 Central ambulations, 959
 Cerebral metabolic activity, 339
 CGS 10746B, 255
 CGS 19755, 767, 893
 ChAT, 7
 Chemical analyses, 629
 Chemical kindling, 329
 Chin rub, 983
 Chiral synthesis, 487
 Chloride flux, 409
 Chlorocitrate, 75
 Chlorpromazine, 129, 775
 Cholinergic, 763
 Chorea, 701
 Chronic cannulation, 449
 Chronic marijuana smoke, 643
 Chronic stress, 283
 Cigarette, 177
 Cigarette brands, 177
 Cigarette smoke, 453
 Cigarette yield, 139
 Classical conditioning, 987
 Cliff avoidance, 241
 Cocaine, 41, 133, 157, 273, 387, 625, 807, 841, 941, 959, 969
 Coffee, 847
 Cognitive expectancies, 115
 Cognitive functioning, 683
 Cold stress, 423
 Conditioned place preference, 443, 987
 Conditioned place preference/aversion, 255
 Conditioned response, 983
 Conditioned suppression of drinking, 787, 795
 Conditioned taste aversion, 717, 983
 Conditioned tolerance, 53
 Conformational analysis, 479
 Conjugates, 523
 Controlled clinical trial, 701
 Convulsions, 157, 297, 329
 Corpus striatum, 399
 Corticosterone, 53, 409, 861
 Corticotropin-releasing factor, 717
 Cortisol, 229
 Cotinine, 177
 p-Coumaroyltyramine, 465
 CPP, 893
 Crickets, 887
 Cross-sectional study, 139, 907
 Cyclic AMP, 565
 Cyclohexyladenosine, 811
 Cyclo(leucyl-glycyl), 881
 Cyclopentyladenosine (CPA), 33
 Cyproheptadine, 433
 Cytochrome P-450, 541
 Cytoskeleton, 617
 Cytotoxins, 629
 D1 receptor, 103
 D2 receptor, 103
 D₁ dopamine receptor, 829
 D₁ receptors, 133
 D₂ receptors, 133
 DA, 7, 571

- Daily marijuana smoking, 691
 Dapiprazol, 125
 Day-old chicks, 173
 Deafferentation pain, 301
 Defecation, 443
 Defense, 781
 Defensive behavior, 751, 819
 Delta-9-tetrahydrocannabinol, 593, 603, 609, 617, 643, 651, 677
 Delta-9-THC, 581
 Desensitization, 565
 Determination, 465
 Deuterium NMR, 553
 Dexamethasone, 717
 Dextromethorphan, 381
 Dextrorphan, 381
 Diamine oxidase, 359
 Diastereomeric solute-solute interaction, 491
 Diazepam, 109, 739, 787
 Diazepam and β -carbolines, 335
 Diethyl ether, 767
 Diltiazem, 801
 Dimethylheptyl side chain, 471
 Diphenhydramine, 191
 Discrimination, 745
 Dog, 17, 523
 Domestication, 751
 Domperidone, 209
 DOPAC, 7
 Dopamine, 21, 133, 181, 191, 241, 255, 305, 387, 571, 603, 841, 915, 923, 959, 969, 1001
 Dopamine receptor supersensitivity, 881
 Dopamine release, 399, 587
 Dopamine transport, 387
 Dopamine turnover, 399
 Dopamine uptake, 399
 Dopaminergic receptors, 157
 Dorsal hippocampus, 169, 181
 Dorsal raphe nucleus, 1001
 Dose-response, 929
 Double-blind, 701
 Drinking, 125, 923
 Dronabinol, 695
 Drug abuse, 381, 571
 Drug addiction, 571
 Drug discrimination, 757
 Drug interactions, 121
 Drug-membrane interactions, 553
 Drugs of abuse, 273
- Eating, 867
 Eating behavior, 185
 EEG, 97, 215, 351
 Efficacy, 701
 Egg jelly coat, 609
 Electrical stimulation, 323
 Electrochemistry, 571
 Electroencephalogram, 771
 Electron microscopy, 671
 Electroshock, 297
 Eledoisin, 977
 Emesis, 345
 Emotional stress, 287
 Enantiomeric purity, 491
 β -Endorphin, 79
 Energy expenditure, 203
 Enkephalin, 771
 Enzyme analysis, 847
 Epoxide-diol pathway, 523
 1S,2R-Epoxy intermediate, 541
 Escape, 835
- Escape response, 323
 Estradiol, 603
 Estrogen-induced LH release, 335
 Ethanol, 767, 923
 Ethanol tolerance, 261
 Ethological analysis, 847
 N-Ethyl-carboxamido-adenosine (NECA), 33
 Event-related potentials, 683
 Ex-smokers, 995
 Excitatory amino acids, 949
 Exploration, 169
 Exploratory behavior, 7
 Extract of Ginkgo biloba (EGb 761), 367
 ($-$)-5¹⁸F- Δ^8 -THC, 503
 Fat, 861
 Fear, 819
 Feeding behavior, 83, 853, 861
 Feeding pattern, 867
 Felbamate, 109
 Fenfluramine, 267
 Fertilization, 609
 Feruloyltyramine, 465
 Fetus, 97
 FG-7142, 169
 Fine movements, 959
 Fixed-interval, 775
 Fixed-interval schedule, 1
 Flavor preference, 717
 ($-$)-5'-Fluoro- Δ^8 -THC, 509
 ($-$)-11-Fluoro- Δ^8 -THC, 509
 Fluoxetine, 311
 cis-Flupenthixol, 317
 Flurazepam, 581
 Focal interictal activity, 351
 Food intake, 27, 75, 133, 185
 Formalin test, 197, 317
 Freely moving rat, 959, 969
 Frontal cortex, 7
 Fullness, 185
 Functional disability, 701
 Fungicide, 775
 Furosemide, 163
- G protein, 559, 565, 1053
 GABA, 329, 429
 GABAergic mechanism, 287
 GABA receptor, 109
 GABOB, 359
 Gamma-aminobutyric acid, 581
 Gamma-butyrolactone (γ -BL), 969
 Gas chromatography/mass spectroscopy (GC/MS), 517, 701
 Gas exchange, 17
 Gastric emptying, 75
 Gender, 203, 229
 Gene expression, 617
 Genetic model, 409
 Genital, 151
 Gepirone, 795
 Gerbil, 533
 Glucose metabolism, 625
 Glucosides, 523
 Glucuronides, 523
 L-Glutamate, 767
 Glutamate receptor, 949
 Glycosylation, 565
 Golgi, 671
 Gonadal hormones, 901
 Guinea pig, 129, 533, 541
 Guinea pig isolated ileum, 581
- Half-life of CBD, 517
 Haloperidol, 41, 399, 1001
 Halothane, 767
 Hamster, 533
 Handling habituation, 409
 Hashish smoking behavior, 115
 Heart rate effects, 691
 Heat loss, 709
 Heat production, 709
 Hedonics, 185
 Heroin, 339, 841
 Hexahydrocannabinol, 533, 553
 5-HIAA, 7, 267
 "High", 657
 High pressure, 305
 Hindlimb grip response, 241
 Hippocampus, 7, 345, 671
 Histamine, 191
 Histamine H1 receptor antagonist, 191
 Homovanillic acid, 191, 587
 Hooded rats, 215
 5-HT, 7, 267, 1041
 5-HT₁, 1009
 5-HT_{1A}, 221, 1019
 5-HT_{1C}, 1019
 5-HT₂, 1009, 1019
 5-HT₃, 1009
 5-HT₄, 1009
 5-HT_{1B} agonists, 279
 5-HT_{1A} receptors, 1041
 5-HT₃ receptor, 151, 1033
 5-HT serotonergic receptors, 751
 Hu-210, 461
 Human, 691, 835
 Hunger, 185, 867
 Huntington's chorea, 701
 Huntington's disease, 701
 6-Hydroxydopamine, 399, 923
 9 α -Hydroxy-hexahydrocannabinol, 479
 9 β -Hydroxy-hexahydrocannabinol, 479
 5-Hydroxyindoleacetic acid, 587
 Hydroxylation, 523
 2-Hydroxypyputrescine, 359
 5-Hydroxytryptamine, 301
 Hyperbaric conditions, 197
 Hyperphagia, 901
 Hypothalamus, 853
 Hypothermia, 129, 261, 465, 541, 581, 901
 Hypoxia, 1
- Ibotenic acid, 181
 Ibotenic acid lesion, 169
 ICI D7114 metabolite, 249
 ICSS, 571
 Ileum, 345
 Illumination, 215
 Imbalanced diet, 83
 Inactivity, 69
 Inhalation, 637
 Interaction, 625
 Intracerebroventricular, 807
 Intrapерitoneal, 449
 Intrathecal, 449
 In vivo electrochemistry (voltammetry)
 presynaptic release, 969
 In vivo voltammetry (electrochemistry)
 ambulations, 959
 ($-$)-2-Iodo- Δ^8 -THC, 509
 ($-$)-5'-Iodo- Δ^8 -THC, 509
 Ion trap MS, 517
 Ionophores, 609
 Iprindole, 881

- Ipsiapirone, 739
 Isolation, 279, 465
 Isoniazid, 109, 329
 Isoproterenol, 249
 Kappa receptor, 125, 129
 Ketamine, 399
 Kindling, 893
 Kitanserin, 1009
 Lateral hypothalamus, 323
 Learning, 79
 Learning and memory, 949
 Lesioning, 923
 Lever-press, 875
 Ligand binding, 461, 471
 Ligands, 1009
 Light/dark test, 733, 739
 Lithium, 983
 Lithium chloride, 717
 Liver, 533
 Liver microsomes, 541
 Locomotion, 169
 Locomotor activity, 21, 121, 215, 255, 381, 399, 423, 509, 811, 841, 881, 941
 Locomotor balance, 367
 Locomotor response, 181
 Long-sleep and short-sleep mice, 941
 Long-term effects, 683
 Long-term memory, 173
 Long-term potentiation, 893
 Lorazepam, 429
 Lung, 637, 663
 Lung injury, 629
 Macrophage morphology, 643
 Macrophage protein, 643
 Macrophages, 663
 Male and female rats, 901
 Male rat, 443
 Man, 523
 Mapping, 351
 Marihuana, 513, 609
 Marijuana, 97, 487, 517, 571, 629, 637, 651, 657, 663, 671, 701
 Marijuana smoke, 677
 Masculine behavior, 221
 Mass spectrometry, 523, 533
 Matching-to-sample, 417
 Maximal electroshock seizures, 109
 Mazindol, 941
 MDMA, 433, 915
 Meals, 867
 Membrane interaction, 547
 Memory, 1, 79
 Memory impairment, 701
 Memory modulation, 417
 Menstrual, 995
 5-MeODMT, 311
 Mesencephalic central gray area, 323
 Mesolimbic reward system, 923
 Metabolites, 487
 Met-enkephalin, 449
 Methylatropine, 745
 N-Methyl-D-aspartate, 767
 5-Methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine (MK-801), 767
 Methylenedioxymethamphetamine, 443
 Methyl naltrexone, 771
 Methylphenidate, 757, 775
 Methylphenidate enantiomers, 875
 Methylxanthine, 847
 Methylxanthine-benzodiazepine interaction, 723
 Mice, 65, 261, 279, 581, 767, 847
 Microdialysis, 387, 571, 587
 Microfilaments, 617
 Microinjection, 33
 Microphotometry system, 423
 Microsomes, 533
 Microtubules, 617
 Midazolam and caffeine complications, 723
 Midazolam pharmacokinetics, 723
 MK-801, 21, 291, 893, 949
 Molecular biology, 1053
 Molecular modeling, 471, 1019, 1033
 Molecular orientation, 553
 Monkey brain, 677
 Monkeys, 671
 Monoamine oxidase, 359, 751
 Monoamine oxidase inhibitors, 915
 Monoamines, 409
 Mood, 229
 Morphine, 21, 27, 283, 317, 771, 819, 887
 Morphology, 637
 Morphometry, 671
 Motion sickness, 345
 Motor activity, 103
 Motor behavior, 305, 763
 Motor cortex, 351
 Motor incoordination, 465
 Mouse, 103, 323, 399, 533
 Mouse lines, 283
 Mouse peritoneal cells, 559
 Multiple schedule, 41, 775
 Muscarinic, 763
 Muscarinic cholinergic receptor, 677
 Muscarinic receptor subtypes, 345
 Myorelaxation, 261
 NA, 7
 Naloxone, 283, 297, 323, 339, 819, 887
 Naltrexone, 79, 185, 443, 771, 807
 Neck muscle activity, 367
 Negative contrast, 433
 Neonatal, 291
 Neonatal mice, 241
 Neostriatal dopamine, 423
 Neuroblastoma cells, 565
 Neuroleptics, 1001
 Neurological disease, 701
 Neuronal plasticity, 893
 Neuropeptide-Y, 417
 Neurotoxic effects, 241
 Neurotoxicity, 915
 Neurotoxicology, 671
 Neurotoxins, 923
 Never-smokers, 995
 Nicotine, 53, 121, 177, 203, 229, 453, 995
 Nicotine compensation, 139
 NMDA, 841
 NMDA antagonist, 291
 NMDA receptor, 893
 Nociception, 197
 (−)-11-Nor-Δ⁹-tetrahydrocannabinol-9-carboxylic acid, 487
 Noradrenaline, 173
 α-Noradrenergic receptors, 853
 Norepinephrine, 241, 853
 NPY, 417
 Nucleus accumbens, 21, 181, 399, 841, 923, 959, 969
 Obesity, 853
 Object recognition, 7
 Obsessive-compulsive disorder, 311
 Odor preference, 781
 Ofloxacin, 65
 8-OH-DPAT, 221, 311, 739, 1009
 Olfactory cortex, 351
 Olfactory discrimination, 241
 Olfactory lobe, 241
 Ondansetron (GR38032F), 739
 Ontogeny, 811, 829
 Open field, 7
 Operant, 835
 Operant behavior, 745
 Operant responses, 249
 Opiate, 771, 819
 Opiate antagonist, 79
 Opiate receptor, 887
 Opioid, 129, 297, 571, 819
 Opioid antagonist, 5, 185
 Opioid systems, 807
 Optical purity, 491
 Oral administration, 517, 701
 Orgasm, 151
 Oxidants, 663
 Oxytocin, 27, 261
 Pain, 283
 Palliative care, 695
 Panic disorder, 723
 Paraoxon, 929
 Paraventricular nucleus, 853
 Pathology, 637
 PCPA, 433
 Penicillin, 351
 Pentobarbital, 767, 801
 Pentylenetetrazol, 109, 297, 329
 Pentylenetetrazole, 581, 987
 Perinatal, 847
 Peripheral nerve injury, 301
 Peripheral-type benzodiazepine receptors, 409
 PET, 503
 Phantom limb pain, 301
 Pharmacokinetics of CBD, 517
 Pharmacophore, 1033
 Pharmacotoxicity, 465
 Phencyclidine, 381, 767
 Phenoxybenzamine, 399
 Phentolamine, 709
 2-Phenylaminoadenosine (CV-1808), 33
 N-Phenylbiguanide, 739
 Phenylisopropyladenosine, 811
 Phospholipase A₂, 609
 Phospholipases, 559
 Physical activity, 203
 Physical dependence, 801
 Picrotoxin, 21, 329
 Pig, 17
 Pigeons, 41
 Pimozide, 317
 Piracetam, 1
 Placebo, 517, 701
 Plasma cotinine, 139, 907
 Plasma delta-1-tetrahydrocannabinol, 517
 Plasma delta-9-THC, 517
 Plasma levels of CBD, 517, 701
 Plasma nicotine, 139, 907
 Plasma testosterone, 287
 Posture, 367
 Predictability, 787, 795
 Premature ejaculation, 221
 Prenatal, 599

- Prenatal administration, 191
 Prenatal exposure, 429
 Prenatal nicotine, 991
 Preoptic area, 33
 Prepartum, 847
 Pressure reversal, 197
 Presynaptic, 571
 Preweanling, 291
 Primary sequence, 1053
 Primates, 637
 Proactive interference, 417
 Proconflict, 787
 Prolactin, 603
 Propranolol, 399
 Proton NMR, 491
 Psychogenetic selection, 7
 Psychomotor performance, 723
 Psychomotor stimulant, 775, 959
 Psychopharmacological activity, 479
 Puffing behavior, 177
 Puffing topography, 139, 907
 Pulmonary alveolar macrophages, 629
 Pulmonary function tests, 663
 Pulmonary resistance, 17
 Pulse rate, 701
 Pyridostigmine, 17, 745
 Pyrilamine, 433
 Quinine, 209
 Quinpirole, 317
 Rabbit, 533
 Raclopride, 133, 209
 Radial maze, 7
 Radioligand binding, 345
 Rat, 1, 33, 75, 83, 121, 125, 133, 197, 209, 339, 417, 453, 523, 533, 599, 671, 709, 717, 745, 757, 775, 801, 829, 875, 983, 987
 Rat brain, 677
 Rat testis, 625
 Rearing behavior, 959
 Receptor, 83, 941, 1019
 Receptor blockers, 237
 Receptor models, 1019
 Rectal temperature, 509
 Reference memory, 417
 Reinforcement, 41, 229, 571, 959, 1001
 Release, 571
 Reproductive system, 599
 Respiratory carbon monoxide, 139, 907
 Response requirements, 273
 Retest reliability, 139
 Retrieval, 1
 Reward, 443, 571
 Ring immobility, 509
 RNA synthesis, 603
 RO40-2148, 249
 Roman strains of rats, 7
 Runway, 125
 S49 Lymphocytes, 559
 Saccharin, 209, 717
 Safety, 701
 Salt appetite, 163, 977
 SCH 23390, 133, 157, 317, 829
 Schedule-controlled behavior, 875, 929
 Scopolamine, 21
 Sea urchin, 609
 Secalonic acid D, 241
 Second messenger systems, 1053
 Sedation, 79, 335
 Seizure threshold, 359
 Selective attention, 683
 Selective breeding, 283
 Self injury, 79
 Self-administration, 41, 807
 Self-induced nonequivalence, 491
 Self-stimulation, 273, 571
 Seminal plugs, 443
 Sensory-specific satiety, 185
 Serotonin, 83, 151, 311, 433, 733, 739, 901, 915, 959, 969, 1001, 1019, 1033, 1041
 Serotonin_3 , 83
 Serotonin receptors, 1009, 1053
 Serotonin_{1A} receptors, 1041
 Serotonin reuptake, 923
 Sertraline, 923
 Sesame oil, 701
 Sesame oil vehicle, 517
 Sex differences, 819
 Sexual arousal, 287
 Sexual attractivity, 221
 Sexual behavior, 221
 Sexual climax, 151
 Shock-induced fighting, 69
 Short-term memory, 417
 SHR, 157
 Side effects, 701
 SKF 38393, 317
 Sleep, 33
 Sleep latency, 65
 Sleeping time, 65
 Smoke absorption, 139
 Smoke exposure, 907
 Smokers, 203, 995
 Smoking, 177, 229, 637, 663
 Smoking cessation, 937
 Smoking profile, 651
 Social attraction, 781
 Sodium excretion, 163
 Sodium pentobarbital, 65
 Solid state NMR, 553
 Spatial memory and sex differences, 991
 Species difference, 541
 Sperm, 609
 Spontaneous alternation, 311
 Spontaneous firing rate restoration, 367
 Staircase Test, 7
 Stereospecificity, 461
 Stereotyped behaviour, 191
 Stereotypy, 381
 Steroid receptors, 861
 Stress, 197, 297, 763
 Striatum, 7, 305, 587, 829
 Structure-activity relationship, 479, 1033, 1041
 Subjective effects, 115, 691
 Submandibular gland, 345
 Successive, 433
 Sucrose, 209, 983
 Sulpiride, 157
 Superior colliculus, 215
 Supportive care, 695
 Suppositories, 497
 Sweet taste, 995
 Swim stress, 409
 Swim-induced analgesia, 283
 Swimming, 241
 Symptoms, 701
 Synaptic loss, 367
 Synaptic plasma membrane, 547
 Synaptic reoccupation, 367
 Tachykinins, 977
 Tail-tremor, 453
 Tar, 651, 657
 Tetrahydrocannabinoid, 491
 Tetrahydrocannabinol, 115, 533, 547, 553
 Δ -Tetrahydrocannabinol, 571
 Δ^1 -Tetrahydrocannabinol, 559
 Δ^2 -Tetrahydrocannabinol, 657
 THC, 513, 571, 587, 599, 625, 671, 695
 Δ^9 -THC, 571
 THC esters, 497
 THC infusion, 691
 THC plasma levels, 691
 Therapeutic effects, 701
 Thermoregulatory behavior, 249
 Thiosemicarbazide, 287
 Thirst, 867
 Three-bottle test, 209
 Three-dimensional, 1033
 Tissue glutathione, 513
 Tobacco, 629, 663, 937
 Tolerance, 97, 121, 283, 887
 Toxicity, 513, 701
 Trachea, 345
 Training stimulus intensity, 173
 Transmitters, 61
 Triadimefon, 757, 775
 Triazolam, 835
 Triazole, 775
 $(-)$ -5'-Trifluoromethyl- Δ^8 -THC, 509
 Triggering, 173
 Tryptophan, 301
 Tryptophan hydroxylase, 751
 Tubulin, 617
 Tunicamycin, 565
 Tunnel maze, 121
 Two-bottle test, 209
 Tylenol, 513
 Tyrosine hydroxylase, 593
 U50,488H, 125, 129
 Umespiron, 89
 Uncontrollable shock, 69
 Urethra, 151
 Urination, 443
 Urine, 523
 Urine volume, 163
 Vasopressin, 27
 Ventilation blocking, 907
 Ventral hippocampus, 169
 Vervet monkey, 267
 Vestibular compensation, 367
 Vestibular nuclei, 367
 Vestibulo-collic reflex, 367
 Visual perception, 689
 Voltammetry, 305, 571
 Water intake, 133
 Whole blood serotonin, 267
 Wistar rat, 221
 Withdrawal, 937
 Working memory, 7, 417
 X-ray diffraction, 547
 Yohimbine, 781
 Zocopride, 733
 Zucker rats, 853

AUTHOR INDEX

- Abbott, F. V., 301
 Abraini, J. H., 305
 Adler, M. W., 129
 Ahlers, S. T., 417
 Ahmad, M., 847
 Ahmed, K. M., 513
 Airaksinen, M. M., 177
 Ajarem, J. S., 847
 Akiyama, K., 423
 Akunne, H. C., 387
 Ali, S. F., 637, 643, 677
 Allen, A. R., 775
 Allender, J., 701
 Antelman, S. M., 53
 Anwer, J., 625
 Araki, Y., 453
 Asin, K. E., 1001
 Audette, C. A., 559
 Avgustinovich, D. F., 751
 Awad, I. R., 853
- Bacciarelli, C., 163
 Baek, S.-H., 487
 Bailey, J. R., 637, 643, 677
 Banijamali, A. R., 509, 553
 Banks, W. A., 771
 Bardelay, C., 7
 Bardo, M. T., 829
 Barnes, N. M., 89
 Barron, J. L., 79
 Bartke, A., 593
 Bättig, K., 121, 139, 907
 Beals, T. F., 637
 Behrens, M., 781
 Bemis, K. G., 103
 Berge, O.-G., 197
 Berkery, D., 609
 Bernardi, M., 191
 Beverly, J. L., III, 83
 Bidzseranova, A., 61, 237
 Bišky, E. J., 443
 Blanchard, D. C., 819
 Blanchard, R. J., 819
 Blass, E., 185
 Bliss, R. E., 937
 Bradley, E., 129
 Brammer, G. L., 267
 Breese, G. R., 875
 Bresnahan, E. L., 949
 Breuer, A., 461
 Bridger, W. H., 311
 Britton, K. T., 717
 Broderick, P. A., 959, 969
 Broderick, W., 547
 Brown, N. K., 533
 Browne, S. E., 581
 Bruhwyl, J., 1
 Bryda, M., 785
 Burstein, S. H., 559
- Cabral, G. A., 643
 Caggiula, A. R., 53
 Calcagnetti, D. J., 255
 Caldarola-Pastuszka, M., 901
 Camí, J., 115
 Campbell, A. D., 941
- Carboni, G., 329
 Carlisle, H. J., 249
 Carlson, J. N., 781, 785
 Carr, R. L., 929
 Carver, E. S., 157
 Castañeda, E., 587
 Cazala, P., 323
 Chambers, J. E., 929
 Champion-Dorow, T. M., 565
 Chang, M. C., 609
 Chang, P., 651, 657
 Charalambous, A., 503, 509,
 553
 Chávez, D., 603
 Chee, S.-J., 215
 Chen, K., 1053
 Cheng, Y., 97
 Cherek, D. R., 835
 Chesley, S., 429
 Chiavegatto, S., 191
 Chleide, E., 1
 Cicciocippo, R., 163
 Cohen, C., 121
 Compton, D. R., 471, 479,
 509
 Consroe, P., 517, 701
 Cook, C. E., 691
 Corda, M. G., 329
 Costall, B., 89
 Costello, N. L., 781, 785
 Cowan, K. A., 835
 Croix, D., 599
 Crowe S. F., 173
 Cuadra, G. R., 69
- Daniell, L. C., 767
 David, V., 323
 De Caro, G., 163, 977
 de Castro, J. M., 867
 Decena, J. A., 97
 de Costa, B. R., 387
 Delacour, J., 7
 De La Torre, R., 115
 Delconte, J. D., 443
 de Lima, T. C. M., 297
 Devane, W. A., 461
 Dewey, S. L., 503
 Dhali, J., 603
 Diamantis, W., 109
 Dib, B., 449
 Dilsaver, S. C., 763
 Dorneney, A. M., 89
 Donoso, A. O., 335
 Dormer, K. N., 987
 Doyle, S. A., 559
 Drewnowski, A., 995
 Drucker, G. E., 881
 Dukat, M., 1009
- Eckerman, D. A., 757, 875
 Eldridge, J. C., 593
 Elsohly, M. A., 497
 Emrich, H. M., 689
 Engh, K., 881
 Enginar, N., 65
 Epstein, L. H., 53, 203
- Eroğlu, L., 65
 Erwin, V. G., 941
 Esseling, K., 351
 Evans, S. M., 1033
 Ez-Zaher, L., 367
- Falk, J. L., 723
 Fernández-Ruiz, J. J., 593
 Fields, J. Z., 881
 Finkelstein, J. A., 853
 First, M. W., 629
 Flaherty, C. F., 433
 Fligel, S. E. G., 637
 Fournier, D., 547
 Fox, A. M., 683
 Frances, H., 279
 Frank, R. A., 273
 Franklin, K. B. J., 317
 Frau, V., 329
 Friedman, E., 311
 Friend, F. L., 509
 Fuller, S. A., 339
 Furset, K., 197
 Furuno, K., 453
- Galdes, A., 1033
 Gall, M., 1033
 Gallaher, T., 1053
 Galpern, W. R., 429
 Garcia, A. W., 995
 Garcia-Cabrera, I., 197
 Gardner, E. L., 571
 Gargiulo, P. A., 335
 Garofalo, P., 949
 Garvey, A. J., 937
 Gauvin, D. V., 987
 Gearhart, G. M., 853
 Geller, E. B., 129, 267
 Gels, M., 109
 Gerrard, P. A., 89
 Gibbs, M. E., 173
 Gibson, B. M., 781
 Gietzen, D. W., 83
 Gilbert, D. G., 229
 Giorgi, O., 329
 Glennon, R. A., 1009, 1019
 Glick, S. D., 781, 785
 Gliederer, F., 651, 657
 Gohda, H., 541
 Gómez, M. A., 887
 Gomita, Y., 453
 Gong, H., Jr., 663
 Goodwin, G. A., 291
 Gordon, J. H., 881
 Gordon, R., 109
 Gorter, R. W., 695
 Graziani, M., 125
 Greenblatt, D. J., 429
 Greig, N., 387
 Grigson, P. S., 433
 Grubner, O., 629
 Gueron, J., 61
 Guerra, D., 115
 Guillet, R., 811
 Gulati, K., 27
- Haensel, S. M., 221
 Halldin, M. M., 487
 Hanisch, W., 689
 Harland, E., 497
 Harvey, D. J., 523, 533
 Hasegawa, T., 359
 Hashimoto, H., 359
 Heinrichs, S. C., 717
 Heller, B., 949
 Hetherington, M. M., 185
 Hetrick, W. P., 79
 Hicks, R. E., 691
 Hikal, A., 497
 Ho, I. K., 157
 Höfer, I., 139, 907
 Hoh, J., 763
 Holloway, F. A., 987
 Horn, E., 351
 Hoskins, B., 157
 Howlett, A. C., 565
 Hrupka, B. J., 83
 Huang, X., 915
 Hubbell, C. L., 443
 Huber, G. L., 629
 Hui, K. K., 651, 657
 Hui, R. A. H. F., 491
 Hunter, S. A., 559
 Hurd, M., 709
 Husain, S., 513, 625
- Ingram, D. K., 949
 Inoue, K., 893
 Irfune, M., 399
 Ishizuka, Y., 157
- Jacob, R. G., 203
 Jaekle, R. S., 763
 Jaffe, J. H., 381
 Jaskiw, G. E., 169, 181
 Jeffcoat, A. R., 691
 Jhanwar-Uniyal, M., 853
 Jodogé, C., 261
 Johnson, D. N., 733, 739
 Johnson, M. P., 915
 Johnson, M. R., 471
 Jones, B. C., 941
- Karoum, F., 181
 Kastin, A. J., 771
 Katayama, K., 893
 Kellogg, C. K., 811
 Kelly, M. E., 89
 Kemble, E. D., 781
 Kennedy, K., 517, 701
 Kent, S., 709
 Kim, T., 861
 Kleinman, J. E., 181
 Klingbiel, P., 261
 Knight, K. C., 151
 Knopf, S., 53
 Kobayashi, H., 465
 Kolonen, S., 177
 Koob, G. F., 717, 841
 Korpi, E. R., 409
 Krähling, H., 89

- Krasnow, S. H., 695
 Kulikov, A. V., 751
 Kyprianou, T., 209
 Lacour, M., 367
 Laguna, J., 701
 Landsberg, L., 937
 Lane, M., 695
 Lau, C. E., 723
 Laughton, W. B., 75
 Layer, R. T., 21
 Lecca, D., 329
 Legros, J. J., 261
 Leibowitz, S. F., 853, 861
 Leonardelli, J., 599
 Lin, S., 509
 Lipska, B. K., 169, 181
 Little, P. J., 471
 Little, T. L., Jr., 497
 Liu, W.-F., 745
 Lowinson, J. H., 571
 Lucot, J. B., 345
 McDonald, S. A., 691
 McGaughey, G. B., 479
 McGuire, M. T., 267
 McKenna, K. E., 151
 McMahon, L. L., 565
 MacLeod, K. B., 983
 MacPhail, R. C., 757, 775
 Makriyannis, A., 503, 509, 547, 553
 Manderscheid, P. Z., 273
 Manzini, S., 163
 Marciñak, G., 503, 509, 553
 Marek, P., 283
 Martin, B. R., 471, 479, 509
 Martinez, R., 129
 Massi, M., 163, 977
 Matsunaga, T., 465
 Mavromoustakos, T., 547
 Mayers, R., 151
 Mechoulam, R., 461, 471, 523
 Mele, A., 387
 Meliska, C. J., 229
 Melvin, L. S., 471
 Mercier, M., 1
 M'Harzi, M., 7
 Michie, P. T., 683
 Miller, L. G., 429
 Modell, H. I., 17
 Molina, V. A., 69
 Monier, C., 279
 Montella, P. G., 241
 Morgan, M. J., 317
 Morimoto, K., 893
 Mos, J., 221
 Moss, D. E., 587
 Moy, S. S., 875
 Murphy, L. L., 593, 603
 Muscat, R., 209
 Muth, N. J., 949
 Myers, R. D., 923
 Nakajima, T., 359
 Nakao, J., 359
 Narimatsu, S., 541
 Naumenko, E. V., 287
 Naylor, R. J., 89
 Nelson, D. L., 1041
 Nelson, D., 75
 Nencini, P., 125
 Neri, C. L., 79
 Newport, G. D., 677
 Newton, S. C., 603
 Ng, K. T., 173
 Nichols, D. E., 915
 Nil, R., 139, 907
 Nomoto, M., 399
 Noto, T., 359
 Oddie, S. D., 587
 Odear, D. F., 479
 Olivier, B., 221
 Orlandi, M., 329
 Orozco, S., 867
 Osman, M., 209
 Panerai, A. E., 449
 Panocka, I., 283
 Parker, L. A., 983
 Patrick, K. S., 875
 Paule, M. G., 637, 643, 677
 Pearson, M. A., 771
 Peck, J. A., 763
 Pedigo, N. W., Jr., 829
 Penke, B., 61
 Perez-Reyes, M., 691
 Perfumi, M., 163
 Perkins, A. N., 757, 875
 Perkins, K. A., 53, 203
 Pert, A., 387
 Pertwee, R. G., 581
 Peters, S. C., 103
 Phillips, G., 209
 Phillips, I., 181
 Plasse, T. F., 695
 Polidori, C., 163
 Pomerleau, C. S., 995
 Pomerleau, O. F., 995
 Pompei, P., 977
 Popova, N. K., 751
 Prescott, W. R., 471
 Pulvirenti, L., 841
 Puustinen, P., 177
 Quarfordt, S. D., 923
 Radcliffe, R. A., 941
 Radulovacki, M., 33
 Rae, G. A., 297
 Rajachandran, L., 291
 Raleigh, M. J., 267
 Ramsey, N. F., 807
 Rapoza, D., 133
 Raskin, L. A., 991
 Rawleigh, J. M., 781
 Ray, A., 27
 Raymond, J., 367
 Razdan, R. K., 471
 Reddy, C. S., 241
 Reggio, P. H., 479
 Reid, A. A., 387
 Reid, L. D., 443
 Reynen, M., 801
 Rice, K. C., 387
 Ritvo, E. R., 267
 Roache, J. D., 835
 Rockhold, R. W., 157
 Rodgers, R. J., 819
 Rodríguez de Fonseca, F., 593
 Rolls, B. J., 185
 Rose, J., 651, 657
 Ross, T. M., 581
 Rostain, J. C., 305
 Roth, M. D., 663
 Rothman, R. B., 387
 Rowlett, J. K., 829
 Sacerdote, P., 449
 Sadowski, B., 283
 Salabarria, J., 75
 Salamanca, S., 901
 Salamone, S., 491
 Samara, E., 523
 Sandman, C. A., 79
 Sandyk, R., 701
 Satinoff, E., 709
 Sato, K., 893
 Saylor, S. S., 53
 Scallet, A. C., 637, 643, 671, 677
 Schechter, M. D., 255
 Schlyer, D. J., 503
 Schram, K., 517, 701
 Schuel, H., 609
 Schuel, R., 609
 Schulkin, J., 977
 Schwartz, M., 273
 Segura, J., 115
 Seltzman, H. H., 479
 Serova, L. I., 287
 Sexton, J. E., 203
 Shader, R. I., 429
 Shannon, H. E., 103
 Sharma, K. K., 27
 Sharpe, L. G., 381
 Shepard, J., 819
 Shepard, K. V., 695
 Sherman, M. P., 663
 Shih, J. C., 1053
 Shimizu, T., 399
 Shiue, C.-Y., 503
 Slikker, W., Jr., 637, 643, 677
 Slob, A. K., 221
 Snider, S., 701
 Sofia, R. D., 109
 Solowij, N., 683
 Sorenson, C. A., 991
 Spangler, E. L., 949
 Sparrow, D., 937
 Spear, L. P., 291
 Spiga, R., 835
 Stanford, D. F., 497
 Steger, R. W., 593
 Stein, E. A., 339
 Stern, L., 701
 Stiller, R. L., 53, 203
 Stinnett, A. L., 643
 Stock, M. J., 249
 Stretton, C. D., 581
 Suemaru, K., 453
 Suh, Y., 991
 Sutoo, D., 423
 Swerdlow, N. R., 841
 Székely, J. I., 381
 Szeto, H. H., 97
 Szirmai, M., 487
 Tahir, S. K., 617
 Takita, H., 423
 Tashkin, D. P., 637, 651, 657, 663
 Tayebaty, J., 977
 Taylor, D. V., 79
 Telegyd, G., 61, 237
 Tempel, D. L., 861
 Thomas, B. F., 471
 Thomas, J. R., 417
 Thompson, D. M., 41
 Thurkauf, A., 387
 Ticho, S. R., 33
 Tirelli, E., 261
 Tomkins, D. M., 89
 Toth, G., 237
 Touchette, P., 79
 Tramu, G., 599
 Tulp, M. Th. M., 345
 Tuominen, K., 409
 Tuomisto, J., 177
 Ugena, B., 115
 Ulak, G., 65
 Uphouse, L., 901
 Uretsky, N. J., 21
 Valeri, P., 125
 van Charldorp, K. J., 345
 van Ree, J. M., 807
 Vervaet, N., 185
 Viet, D., 7
 Voitenko, N. N., 751
 Von Meyer, L., 689
 Wadleigh, R. G., 695
 Wagner, R., 351
 Walker, L., 497
 Wallace, L. J., 21
 Ward, K. D., 937
 Ward, S. J., 471
 Watanabe, K., 465, 541
 Weatherford, S. C., 75
 Weatherspoon, A., 819
 Weber, M. M., 689
 Weinberger, D. R., 169, 181
 Weiss, S. M., 819
 Welzl, H., 121
 Wendl, A., 689
 Wenger, T., 599
 Westkaemper, R. B., 1019
 Westlake, T. M., 565
 Whishaw, I. Q., 587
 White, W. R., 691
 Wichlinski, L., 881
 Williams, H. P., 273
 Williams, T. H., 491
 Williams, T. J., 89
 Willig, F., 7
 Willner, P., 209
 Winsauer, P. J., 41
 Wirtshafter, D., 1001
 Wolf, A. P., 503
 Woolverton, W. L., 133
 Wu, D.-L., 97
 Wu, T.-C., 651, 657
 Yadin, E., 311
 Yamamoto, I., 465, 541
 Yamamoto, M., 861
 Yang, D.-P., 547, 553

Yang, W., 1053
Yoshimura, H., 465, 541
Young, J. B., 937
Young, R., 733, 739

Young, S. N., 301
Yu, J. L., 651, 657
Yutrzenka, G. J., 801
Yuwiler, A., 267

Zabala, N. A., 887
Zahalka, J., 461
Zihl, J., 689

Zimmerman, A. M., 609, 617
Zimmerman, S., 609